Filing Details
- Accession Number:
- 0001181431-11-029016
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-05-12 10:37:44
- Reporting Period:
- 2011-05-11
- Filing Date:
- 2011-05-12
- Accepted Time:
- 2011-05-12 10:37:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1484478 | Furiex Pharmaceuticals Inc. | FURX | Pharmaceutical Preparations (2834) | 271197863 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1181152 | Stuart Bondurant | C/O Furiex Pharmaceuticals, Inc. 3900 Paramount Parkway, Suite 150 Morrisville NC 27560 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-05-11 | 3,300 | $15.25 | 3,896 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (to buy) | $9.11 | 2020-06-17 | 17,570 | 17,570 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2020-06-17 | 17,570 | 17,570 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.24 to $15.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The options were awarded on 6/17/2010 and vest and become exercisable in full on the earlier of the first anniversary of the date of grant or immediately prior to the next election of directors of the Company, provided that the Optionee is still at that time serving on the Company's Board of Directors.